title: The application of Fe3O4 nanoparticles in cancer research: a new strategy to inhibit drug resistance.
abstract: Although much effort has been extended to the efficient cancer therapies, the drug resistance is still a major obstacle in cancer chemotherapeutic treatments. Almost 90% of the cancer therapy failure is caused by the relative problems. Recently, the application of drug coated polymer nanospheres and nanoparticles to inhibit the related drug resistance has attracted much attention. In this report, we have explored a novel strategy to inhibit the multidrug resistance of the targeted tumor cells by combining the unique properties of tetraheptylammonium capped Fe(3)O(4) magnetic nanoparticles with the drug accumulation of anticancer drug daunorubicin. Our results of confocal fluorescence and atomic force microscopy (AFM) as well as electrochemical studies demonstrate the remarkable synergistic effect of Fe(3)O(4) nanoparticles on drug uptake of daunorubicin in leukemia K562 cells. These observations indicate that the interaction between the magnetic nanoparticles Fe(3)O(4) and biologically active molecules on the membrane of leukemia cell lines may contribute to their beneficial effect on cellular uptake so that the synergistic enhanced effect of magnetic nanoparticles Fe(3)O(4) on drug uptake of drug resistance leukemia K562 cells could be observed upon application of the Fe(3)O(4) nanoparticles.
authors.affiliation: State Key Lab of Bioelectronics, Chien-Shiung Wu Laboratory, Southeast University, Nanjing 210096, People's Republic of China. xuewang@seu.edu.cn
authors.forename: Xuemei
authors.initials: X
authors.lastname: Wang
authors.forename: Renyun
authors.initials: R
authors.lastname: Zhang
authors.forename: Chunhui
authors.initials: C
authors.lastname: Wu
authors.forename: Yongyuan
authors.initials: Y
authors.lastname: Dai
authors.forename: Min
authors.initials: M
authors.lastname: Song
authors.forename: Sebastian
authors.initials: S
authors.lastname: Gutmann
authors.forename: Feng
authors.initials: F
authors.lastname: Gao
authors.forename: Gang
authors.initials: G
authors.lastname: Lv
authors.forename: Jingyuan
authors.initials: J
authors.lastname: Li
authors.forename: Xiaomao
authors.initials: X
authors.lastname: Li
authors.forename: Zhiqun
authors.initials: Z
authors.lastname: Guan
authors.forename: Degang
authors.initials: D
authors.lastname: Fu
authors.forename: Baoan
authors.initials: B
authors.lastname: Chen
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology* / Q000627:therapeutic use; D020099:Coated Materials, Biocompatible; D003630:Daunorubicin / Q000494:pharmacology* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D018432:Drug Resistance, Multiple / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005290:Ferric Compounds; D006801:Humans; D020014:K562 Cells; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology; D008280:Magnetics; D053758:Nanoparticles; D000644:Quaternary Ammonium Compounds
chemical_list: D000903:Antibiotics, Antineoplastic; D020099:Coated Materials, Biocompatible; D005290:Ferric Compounds; D000644:Quaternary Ammonium Compounds; C000499:ferric oxide; C055292:tetrahexylammonium; D003630:Daunorubicin